Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1 Interventional

Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors

ClinicalTrials.gov ID: NCT02063958

Public ClinicalTrials.gov record NCT02063958. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Study is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.

Study identification

NCT ID
NCT02063958
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1
Lead sponsor
Esanex Inc.
Industry
Enrollment
19 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 2014 (Actual)
Primary completion
Mar 27, 2017 (Actual)
Completion
Mar 20, 2018 (Actual)
Last update posted
Jul 30, 2018

2014 – 2018

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Mayo Clinic Scottsdale Arizona 85259-5499 —
Stanford Medicine Stanford California 94305 —
Georgetown University Medical Center Washington D.C. District of Columbia 20007 —
Center for Cancer Research, National Cancer Institute Bethesda Maryland 20892 —
hackensack University Medical Center Hackensack New Jersey 07601 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02063958, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2018 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02063958 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →